Liftstream is an executive search recruitment company in the life sciences sector
The European Society for Medical Oncology (ESMO) recently held its annual congress in Vienna, Austria. The congress was a flood with a variety of new and updated clinical data about a number of cancer drugs currently in development. The congress was a blend of big pharma and small innovative biotech’s presenting a wide array of data. Below, Liftstream looks at some of the highlights from the congress.
Oncology drug development is one of the largest areas within the pharmaceutical industry, addressing a disease area that causes more deaths than all other diseases apart from cardiovascular. The current global oncology market is estimated to be in the region of $55bn and forecast to grow to over $70bn by 2016. The oncology market is often seen as the most diverse with a wide range of indications and there are some 900 estimated clinical programmes currently underway. It is estimated that there are more than 200 different forms of cancer and therefore the oncology market presents a unique set of challenges to the industry.
On 26th of April 2012 David Brennan stepped down as AstraZeneca’s CEO after 6 years in the job. David Brennan had risen through the ranks at AstraZeneca first at Astra and later after the merger with ICI spin-off Zeneca. Brennan had been criticised by investors for failing to sure up the companies pipeline as a wave of patents expired. Yet, when Brennan announced he was leaving, AstraZeneca’s share price fell dramatically and took nearly two months to recover.